Your browser doesn't support javascript.
loading
Acute myeloid leukemia: Current understanding and management.
Becker, Michelle; Farina, Kyle A; Mascarenhas, John.
  • Becker M; Michelle Becker practices in the adult leukemia program at the Icahn School of Medicine at Mount Sinai in New York, N.Y. Kyle A. Farina is a clinical pharmacy manager, working on the leukemia service at Mount Sinai Hospital in New York, N.Y. John Mascarenhas is director of the adult leukemia program, leader of the Myeloproliferative Disorders Clinical Research Program in the Division of Hematology/Oncology at the Tisch Cancer Institute at Mount Sinai Hospital, and a professor of medicine at the
JAAPA ; 37(1): 34-39, 2024 Jan 01.
Article en En | MEDLINE | ID: mdl-38128137
ABSTRACT
ABSTRACT Although relatively rare, acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is associated with poor 5-year overall survival and prompt treatment is critical. Classifying AML based on World Health Organization criteria is important for determining prognosis and applying a risk-adapted treatment approach. Throughout therapy, patients require comprehensive supportive care measures with blood product transfusions, antimicrobial treatment, and frequent monitoring for chemotherapy-related complications. This article provides an overview of AML and its treatments. Clinicians in all specialties must be able to recognize the early signs of AML and ensure their patients seek appropriate expert medical care with a hematologist/oncologist.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda Límite: Adult / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda Límite: Adult / Humans Idioma: En Año: 2024 Tipo del documento: Article